Table of Contents
Introduction:
Urinary incontinence involves involuntary leakage of urine triggered by physical exertion, sneezing, or coughing, as well as an urgent need to urinate. While the stress component can be easy to diagnose and manage, the urgency component poses greater difficulty in treatment. Standard management initially involves behavioral therapies, bladder training, and pelvic floor muscle exercises. Sometimes, clinicians opt for treatments targeting the predominant symptom, such as slings, polyacrylamide hydrogel (PAHG), anticholinergics, and beta-3 adrenergic agonists for urinary incontinence. This approach, however, may lead to adverse effects such as postvoid residual urine or urinary tract infections and may not fully address the urgency component.
Given these challenges, a combined therapeutic approach that could effectively address urinary incontinence components is needed. A novel treatment strategy combines intra-detrusor botulinum toxin injections, known for their efficacy in managing urinary incontinence and overactive bladder syndrome, with PAHG injections, which can be used as an alternative to sub-urethral slings.
What Are Bulking Agents?
A bulking agent is an excipient used in the lyophilization (freeze-drying) process to enhance the structure and efficiency of the dried product. These agents are crucial in forming the proper structure of the lyophilized cake, impacting its morphology and pore formation. The primary function of bulking agents is to create a porous structure in the cake, facilitating frozen water's sublimation. Larger pores in the cake allow for more rapid sublimation, thereby reducing the primary drying time of the product.
Bulking agents help achieve aggressive primary drying conditions, as they enable the process to occur at temperatures above the product's glass transition temperature or collapse temperature. Proper use of bulking agents can optimize the lyophilization cycle, especially in biopharmaceutical formulations.
Common bulking agents include mannitol and glycine, which have crystallization tendencies and can influence the eutectic melting temperatures of the product. The choice and concentration of bulking agents are critical, as they affect the protein's physical stability, the cake's appearance, and the final product's reconstitution time. Bulking agents also play roles in tonicity, increasing product mass, and facilitating rehydration of the lyophilized cakes.
What Is Urethral Bulking Injection and Bulking Procedure?
Bulking agents are used to treat isolated intrinsic sphincter deficiency (ISD) without urethral hypermobility or to manage stress urinary incontinence (SUI) in patients who are medically frail and unsuitable for more invasive surgeries. These agents increase the resistance to urine flow at the bladder neck through the coaptation of the urethral lumen. An ideal bulking agent should be biocompatible, easy to inject, have a low complication rate, minimal degradation, and not migrate to other areas of the body. Commonly used bulking agents include glutaraldehyde-cross-linked bovine collagen and pyrolytic carbon-coated zirconium oxide beads with other substances.
Urethral Bulking Injection Techniques:
1. Peri-urethral Injection: In this technique, the patient is positioned in the dorsal lithotomy position. The urethra is numbed with two percent Lidocaine jelly. Using a zero to 30-degree cystoscope, a 22-gauge spinal needle is inserted peri-urethral at the four or eight o’clock position and advanced to the bladder neck in the sub-urothelial plane. A dilute Lidocaine solution may be injected through the needle to enhance anesthesia and confirm the correct placement. Once the needle is positioned correctly, the bulking agent is injected until a visible bulge occludes the urethral lumen. The procedure is then repeated on the opposite side. A cough stress test ensures continence and additional bulking agents are added as needed.
2. Transurethral Injection: This injection involves advancing a specially designed injection needle through the operative port of a zero-degree cystoscope into the mucosa of the urethra just below the internal urethral sphincter. The bulking agent is injected at the four or eight o’clock position until the urethral lumen is visibly occluded. The procedure is repeated on the other side. This method can be performed in an office setting or under local anesthesia, allowing the patient to cough during the procedure to verify continence before completion.
What Are Combination Therapies With Bulking Agents?
1. Combination Therapies With Bulking Agents: This strategy combines therapies with bulking agents to address mixed urinary incontinence (MUI) by simultaneously targeting both stress urinary incontinence (SUI) and urgency urinary incontinence (UUI) components.
2. Types of Bulking Agents: Bulking agents such as mannitol and glycine are commonly used in lyophilized biologics to improve the stability and quality of the final product. Mannitol, in particular, helps preserve the appearance of the lyophilized cake, increases the primary drying temperature, and aids in reconstitution. It is often used with sucrose, which acts as a lyoprotectant. Alternative bulking agents include poly-vinylpyrrolidone (PVP) and cyclodextrin, which are known to increase formulations' glass transition temperature (Tg).
3. Application of Bulking Agents:
-
In mixed urinary incontinence, PAHG treats SUI by increasing outflow resistance at the bladder neck. It augments the urethral lumen, thereby improving urinary control. The technique involves injecting PAHG peri-urethral to create a supportive bulking effect.
-
Botulinum toxin is used to address UUI by reducing overactive bladder symptoms. It works by inhibiting the detrusor muscle contractions that cause urgency and frequency.
-
Combining PAHG with both in toxin therapy provides effective and long-lasting results in SUI and UUI, often resulting in sustained symptom relief. The combination therapy is safe and well-tolerated when administered correctly, even in elderly or frail patients.
-
Treatment outcomes can vary based on the patient’s specific condition, the precise techniques used, and the dosage administered.
-
The success of combination therapy often depends on tailoring the treatments to the individual’s needs, including the type and severity of incontinence.
What Are Bulking Agents for Stress Incontinence?
Stress Urinary Incontinence and Urethral Bulking Agents:
Stress urinary incontinence (SUI) is a common issue that brings many patients to urologists. Treatment options for SUI vary widely, from pelvic floor physiotherapy to various surgical procedures. Among these options, injectable urethral bulking agents offer a less invasive alternative for SUI. Urethral bulking enhances or restores normal mucosal coaptation. The bulking agent injected into the submucosal area would be easily injectable, cost-effective, biocompatible, non-migratory, and cause minimal tissue inflammation. Currently, PAHG is the only injectable bulking agent approved and marketed for SUI.
Conclusion:
Urethral bulking agents provide a valuable non-surgical option for urinary incontinence. While they may not match the effectiveness or longevity of surgical treatments, they are associated with minimal treatment-related morbidity and a low risk of severe adverse events. Clinicians should communicate the benefits and limitations of bulking agents to each patient to ensure their expectations are managed effectively.
